Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2009

View Archived Issues

Boehringer Ingelheim divulges new B-Raf kinase inhibitors for cancer

Array BioPharma and Genentech jointly develop new Akt protein kinase inhibitors for cancer

Novel gamma-secretase inhibitors developed at Schering-Plough

Gilead scientists describe new TLR7 agonists in recent patent

Recent AstraZeneca patent imparts new bacterial DNA gyrase inhibitors

Novel progesterone receptor ligands in development at Bayer Schering Pharma

New deuterium-enriched ezetimibe analogues disclosed by Protia researchers

Novel angiotensin AT2 receptor antagonists disclosed by Servier

Astellas patent covers EP4 receptor antagonists and their use in treating chronic renal failure

Gilead divulges new HIV reverse transcriptase inhibitors

Celsion commences pivotal phase I/II ThermoDox study in breast cancer

FDA issues complete response letter for Risperdal Consta

Genaera presents preliminary phase Ib trodusquemine results

Raltegravir efficacy sustained through 96 weeks, cancer incidence low in HIV studies

C-peptide reduces lung inflammation in hemorrhagic shock model

Breast cancer risk declines following discontinuation of estrogen plus progestin therapy

Interim efficacy analysis for Riquent trial indicates continuation is futile

RAP-041 displays antiangiogenic and antitumor activity

Phase I clinical evaluation of new recombinant factor IX product begins

Osiris reports positive data on stem cell treatment for acute myocardial infarction

DOR BioPharma signs partnering agreement with Sigma-Tau for orBec

Indian DCGI grants market authorization to Emergent's BioThrax anthrax vaccine

National Cancer Institute accepts PharmaGap's PhG-alpha-1 for testing

License agreement signed for elinogrel

Novelos signs agreement for NOV-002 with Mundipharma, closes private placement with Purdue Pharma

Merck & Co. acquires Insmed's follow-on biologics platform

Palatin receives payments from AstraZeneca related to melanocortin receptor collaboration

Adding methotrexate, methylprednisolone to IFN-beta1a not beneficial in relapsing-remitting MS

Ono Pharmaceutical updates recent progress

Gel formulation of UC-781 found suitable for rectal use in humans

Hydroxyfasudil enhances learning and memory in aged rats

Savient updates pegloticase BLA

Cubist starts first-in-human trial for Clostridium difficile infections

Genentech commences pivotal phase II GDC-0449 trial in basal cell carcinoma

Novartis to develop ASA-404 in breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 7, 2025.
House passes H.R. 1, restoring R&D tax cuts
BioWorld MedTech
The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
With surface mimicry, molecular glues shed hairpin need
BioWorld Science
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...